OncLive

Most Recent

Sacituzumab Govitecan Meets Primary End Point in Phase 3 ASCENT Trial

July 6th 2020

By Kristi Rosa

The novel antibody-drug conjugate sacituzumab govitecan-hziy demonstrated significant improvement in survival in patients with triple-negative breast cancer without brain metastases who previously received at least 2 prior therapies for metastatic disease.

Palliative Care Builds Bridges in Oncology Practice

July 6th 2020

By Toby Campbell, MD, MSCI

Toby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.

Expert Highlights Unmet Need for Patients With Metastatic HER2+ Breast Cancer and Brain Metastases

July 6th 2020

By Brittany Cote

Brian Czerniecki, MD, PhD, discusses how patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup.

FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC

July 6th 2020

By OncLive Staff

Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.

FDA Lifts Partial Clinical Hold on Camidanlumab Tesirine R/R Hodgkin Lymphoma Trial

July 6th 2020

By Kristi Rosa

The FDA has lifted a partial clinical hold that was placed on the phase 2 clinical trial of camidanlumab tesirine in patients with relapsed/refractory Hodgkin lymphoma.

Latest Videos

Featured Content

All Content

x